by Elsevier

Derivation and characterization of hCSs. (A) Experimental design of the study. (B) Main growth factors and media used for neural induction and differentiation. DM and SB are SMAD inhibitors; XAV is a WNT inhibitor. (C) PRSs in CTRL (n = 12) and SCZ (n = 10) donors. The 3 non-European donors were excluded as PRS estimates from current genome-wide association studies are more accurate in European populations. PRS data were not available for 2 CTRL donors and 1 SCZ donor. ∗p < .05, two-sided Welch test. (D) Mean volume of all hCSs (n = 28) at each stage of maturation. Error bars indicate SD. (E) Transcriptional trajectories of cell type–specific marker genes showing expected gene expression patterns. ∗p < .05, ∗∗p < .01, two-sided Mann-Whitney test. BDNF, brain-derived neurotrophic factor; CTRL, control; EGF, epidermal growth factor; FGF-2, fibroblast growth factor 2; hCS, human cortical spheroid; iPSC, induced pluripotent stem cell; NT3, neurotrophin-3; PRS, polygenic risk score; SCZ, schizophrenia. Credit: Biological Psychiatry (2023). DOI: 10.1016/j.biopsych.2023.08.017

Schizophrenia is a severe neuropsychiatric disease that remains poorly understood and treated. Schizophrenia onset is typically in adolescence or early adulthood, but its underlying causes are thought to involve neurodevelopmental abnormalities. Because human prenatal and postnatal brain tissue is exceedingly difficult to procure and therefore study, researchers have had limited opportunities to identify early disease mechanisms, especially during the critical prenatal period.

Now, a pair of studies that appear in Biological Psychiatry use new technology to study schizophrenia in models of early human brain development.

The first study used a unique approach involving three-dimensional brain organoids, which are known to recapitulate fetal brain development. The researchers, led by first author Ibrahim A. Akkouh, Ph.D., and senior author Srdjan Djurovic, Ph.D., both at Oslo University Hospital, collected skin cells from 14 patients with schizophrenia and 14 healthy controls and generated induced pluripotent stem cells (iPSCs), which they then manipulated to develop into brain-like cortical spheroids.

The organoids grown from patients and controls differed in their expression of thousands of genes—in line with the finding that the genetic influences on schizophrenia are many and very small. However, among the genes, those associated with neuronal axons stood out as a group.

Dr. Akkouh explained, "We identified persistent axonal dysregulation as an early contribution to disease risk."

Importantly, the researchers assessed organoid maturation at several time points, which enabled them to establish the persistent nature of the disturbances throughout development.

Dr. Akkouh added, "Our findings provide novel and hitherto inaccessible insights into the molecular basis of schizophrenia during early brain development."

In the second study, researchers led by Roy H. Perlis, Ph.D., at Harvard Medical School, focused on a particular genetic risk locus. The schizophrenia risk locus 15q11.2, a particular chromosomal region containing four genes, has a penetrance of over 10%, translating to a doubling of risk for schizophrenia among people carrying an unusual copy number of this genetic region.

One gene in the locus, CYFIP1, has been associated with synaptic function in neurons and confers increased risk for neurodevelopmental disorders including schizophrenia and autism.

CYFIP1 is highly expressed in microglia, the brain's own immune cells, but its function there is unknown. Microglia are known to carry out synaptic pruning, in which they "eat" excess synaptic structures, a process critical to healthy brain development.

Dr. Perlis and colleagues collected blood cells from healthy volunteers and isolated iPSCs, which they then manipulated to differentiate into microglia-like cells. The researchers then used CRISPR technology to remove functional CYFIP1 from the cells.

Dr. Perlis said of the work, "Our findings suggest that changes in the behavior and function of microglia due to aberrant CYFIP1 function, such as through coding or copy number variants, could affect microglial processes such as synaptic pruning, homeostatic surveillance, and neuronal maintenance, which are critical for proper brain development and function."

"This could contribute to CYFIP1-related neurodevelopmental and psychiatric disorders resulting in part from microglia dysfunction. Among the specific disorders linked to variation in CYFIP1 are both autism and schizophrenia."

John Krystal, MD, Editor of Biological Psychiatry, commented, "The biology of schizophrenia is very complex and yet two themes represented by these two studies seem to be very important: the increased rate of elimination of glutamatergic synapses during development, and disturbances in the signaling properties of these glutamate synapses. These two disturbances could perturb circuit function in ways that are critical to development of symptoms and cognitive impairments associated with schizophrenia."

Dr. Perlis added, "More broadly, our findings highlight the importance of looking beyond neurons to understand risk genes. While finding risk loci may be the first step in understanding the role of genes in brain diseases, it's only a first step; figuring out the relevant cell type, and what those genes are doing, is absolutely critical in moving from association to—we hope—actual treatments."

More information: Ibrahim A. Akkouh et al, Longitudinal Transcriptomic Analysis of Human Cortical Spheroids Identifies Axonal Dysregulation in the Prenatal Brain as a Mediator of Genetic Risk for Schizophrenia, Biological Psychiatry (2023). DOI: 10.1016/j.biopsych.2023.08.017

Steven D. Sheridan et al, Loss of Function in the Neurodevelopmental Disease and Schizophrenia-Associated Gene CYFIP1 in Human Microglia-like Cells Supports a Functional Role in Synaptic Engulfment, Biological Psychiatry (2023). DOI: 10.1016/j.biopsych.2023.07.022

Journal information: Biological Psychiatry 

Provided by Elsevier